Posaconazole in human serum: A greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3099-3104

  Lignell, Anders ^a   Löwdin, Elisabeth ^a   Cars, Otto ^a   Chryssanthou, Erja ^b   Sjölin, Jan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POSACONAZOLE; PROTEIN; STEROL 14ALPHA DEMETHYLASE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CLAVISPORA LUSITANIAE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FUNGAL STRAIN; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING;

ANTIFUNGAL AGENTS; CANDIDA; CULTURE MEDIA, SERUM-FREE; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; SERUM; TRIAZOLES;

EID: 79959189647     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01671-10     Document Type: Article

References (21)

1. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
2. Andes, D., et al. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54:2497-2506.
3. Andes, D., et al. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
4. Bekersky, I., et al. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
5. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
6. Courtney, R., et al. 2005. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45:185-192.
7. Craig, W. A., and B. Suh. 1996. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, MD.
8. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
9. EUCAST. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
10. Gage, R., and D. A. Stopher. 1998. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. 17:1449-1453.
11. Gustafsson, I., and O. Cars. 2004. The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae. Clin. Microbiol. Infect. 10:934-937.
12. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:648-653.
13. Kunin, C. M., W. A. Craig, M. Kornguth, and R. Monson. 1973. Influence of binding on the pharmacologic activity of antibiotics. Ann. N. Y. Acad. Sci. 226:214-224.
14. Li, Y., U. Theuretzbacher, C. J. Clancy, M. H. Nguyen, and H. Derendorf. 2010. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin. Pharmacokinet. 49:379-396.
15. Lignell, A., A. Johansson, E. Lowdin, O. Cars, and J. Sjolin. 2007. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole. Clin. Microbiol. Infect. 13:613-619.
16. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, and R. J. Hollis. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40: 852-856. (Pubitemid 34208634)
17. Pfaller, M. A., et al. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn. Microbiol. Infect. Dis. 48:201-205.
18. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46:1032-1037.
19. Ullmann, A. J., et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
20. Walsh, T. J., et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
21. Zhanel, G. G., D. G. Saunders, D. J. Hoban, and J. A. Karlowsky. 2001. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob. Agents Chemother. 45:2018-2022.